Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

Background The combination of nivolumab and ipilimumab has been approved for the treatment of multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Methods Patients with newly diagnosed, stage IVA–IVB SCCHN eligible for cisplatin-based chemotherapy received nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy. The primary endpoint was safety of definitive RIT. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the association of baseline programmed death-ligand 1 (PD-L1) expression as well as on-treatment changes in immune bias with treatment outcomes. Results Twenty-four patients were enrolled. With a median follow-up of 36.1 months, grade 3 or higher treatment-related adverse events were reported in 21 individuals (88%); 5 individuals developed in-field soft tissue ulceration during consolidation immunotherapy, resulting in one fatality. The 3-year PFS and OS rates were 74% (95% CI 58% to 94%) and 96% (95% CI 88% to 100%), respectively. PD-L1 combined positive score (CPS) did not correlate with death or disease progression. Decreases in extracellular vesicle PD-L1 within the concurrent RIT phase were associated with prolonged PFS (p=0.006). Also, interval decreases in circulating interleukin (IL)4, IL9, IL12, and IL17a during concurrent RIT were associated with subsequent ulceration. Conclusions Definitive RIT with nivolumab and ipilimumab has sufficient clinical activity to support further development. Early changes in circulating biomarkers appear able to predict treatment outcomes as well as ensuing in-field soft tissue ulceration. Trial registration number NCT03162731.

[1]  A. Argiris,et al.  In-field toxicity analysis of a phase I clinical trial of nivolumab and ipilimumab with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: In-Field toxicity of immune-RT in LA-SCCHN. , 2023, International journal of radiation oncology, biology, physics.

[2]  J. Machiels,et al.  LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) , 2022, Annals of Oncology.

[3]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Iro,et al.  Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer , 2022, Journal for ImmunoTherapy of Cancer.

[5]  A. Broeks,et al.  Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma , 2021, Nature Communications.

[6]  R. Ferris,et al.  LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 , 2021, Annals of Oncology.

[7]  K. Harrington,et al.  Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.

[8]  A. Argiris,et al.  Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. , 2021, Cancer treatment reviews.

[9]  B. Jeremic,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Chuanzhao Zhang,et al.  Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1 , 2021, Journal for ImmunoTherapy of Cancer.

[11]  H. Iro,et al.  Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 , 2020, Journal for ImmunoTherapy of Cancer.

[12]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[13]  C. Rübe,et al.  Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[15]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[16]  A. Argiris,et al.  Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma , 2019, Front. Oncol..

[17]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[18]  C. R. Leemans,et al.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial , 2019, The Lancet.

[19]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial , 2019, The Lancet.

[20]  J. Bourhis,et al.  Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[22]  M. Fung,et al.  Strategies targeting the IL-4/IL-13 axes in disease. , 2015, Cytokine.

[23]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[24]  K. Ang,et al.  Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. , 2012, International journal of radiation oncology, biology, physics.

[25]  C. R. Leemans,et al.  Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[27]  J. Renauld,et al.  IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[28]  L. Mariani,et al.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[30]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[31]  J. Renauld,et al.  IL-9 Induces Differentiation of TH17 Cells and Enhances Function of FoxP3+Natural Regulatory T Cells , 2009 .

[32]  G. Calais,et al.  Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.